

7 May 2007

## GlaxoSmithKline enters into Agreement with OBJ

=====

OBJ Limited (ASX: OBJ) wishes to announce that it has entered into a short term arrangement with GlaxoSmithKline Consumer Healthcare (GSK) during which GSK will be funding and carrying out exploratory studies to investigate the potential use of OBJ's transdermal drug delivery technology, Dermaportation, for a range of non-prescription healthcare applications.

This arrangement follows a small exploratory study with GSK last year which suggested that OBJ's Dermaportation technology may increase delivery of a specific drug through the skin.

OBJ's Dermaportation technology, and its new Enhanced Transdermal Polymer material, enhance transdermal (through the skin) drug delivery. The technology is applicable to a broad range of drugs and drug delivery environments including applications where chemical and other approaches are unsuitable or unreliable. Transdermal delivery provides a convenient, effective and patient friendly method of drug delivery for both locally acting and systemic drugs.

For further information on OBJ and its technology see the Company's website at [www.obj.com.au](http://www.obj.com.au)

END

**For more information:**

OBJ  
Jeffrey Edwards  
Phone: +61 8 944 33011  
Mobile: 041 791 2211  
E-mail: [jedwards@obj.com.au](mailto:jedwards@obj.com.au)

OBJ  
LIMITED

P  
R  
E  
S  
S  
R  
E  
L  
E  
A  
S  
E